New combo aims to shrink rectal tumors, help patients skip surgery
NCT ID NCT07162714
Summary
This study is testing a two-part treatment for a specific type of rectal cancer. First, patients receive a short, intense course of radiation. Then, they receive an immunotherapy drug called AK112. The main goal is to see if this combination can completely eliminate the tumor, potentially allowing some patients to avoid major surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.